MAP Pharmaceuticals, Inc. (MAPP) Reports Q4 Loss of 45c/Share; to Restate Interim Statements for First 3 Qtrs. of 2011
Tweet
Share
E-mailGet Alerts MAPP Hot Sheet
Price: $28.16 +0.64%
Financial Fact:
Collaboration revenue: 878K
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Collaboration revenue: 878K
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) reported Q4 EPS of ($0.45), $0.14 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $837 thousand versus the consensus estimate of $2.74 million.
To restate interim statements for the first three quarters in 2011. Cites the accounting treatment of a $60 million upfront payment.
For earnings history and earnings-related data on MAP Pharmaceuticals, Inc. (MAPP) click here.
To restate interim statements for the first three quarters in 2011. Cites the accounting treatment of a $60 million upfront payment.
For earnings history and earnings-related data on MAP Pharmaceuticals, Inc. (MAPP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- Bernstein remains bullish on SpaceX but sees challenges in telecom ambitions
- Beike (BEKE) PT Raised to $23 at Morgan Stanley
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
